Skip to main navigation Contact Us About Us Pipeline Technology Clinical Trials Investors Careers You are here: Home / Investors Investor Relations Investors Press Releases Events & Presentations Corporate Governance Corporate Responsibility Financials & Filings Analyst Coverage Stock Information Investor FAQs Contact Us Email Alerts Tools Shareholder Tools Print Share Investors Latest Presentation Nov 09, 2021 Corporate Presentation Download Latest Analyst Day There are currently no events to display. Latest Conference Call Nov 08, 2021 at 4:30 PM EST Q3 2021 Xencor, Inc. Earnings Conference Call Listen to Webcast Company Profile Since Xencor’s founding in 1997, investors have been drawn to our remarkable scientific capabilities around engineering monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. We engineer monoclonal antibodies, and now cytokines, for the potential treatment of patients with cancer and autoimmune diseases. Currently, 20 candidates engineered with our XmAb® technology are in clinical development internally and with partners, which include Novartis, Genentech, Amgen, Alexion, MorphoSys and Gilead, among others. Our XmAb engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. The most recent expansion of our technology is the XmAb bispecific Fc domain, which enables the rapid design and simplified development of antibodies that bind two or more different targets simultaneously and other protein structures, as well. We have used bispecific Fc domains to generate a broad array of novel drug candidates, including: bispecific antibodies that contain an anti-tumor associated antigen binding domain and a second binding domain targeted to CD3, an activating receptor on T cells; bispecific antibodies that promote tumor-selective T-cell activation by targeting multiple checkpoint or co-stimulatory receptors; and cytokines that are potency tuned to improve therapeutic index. The plug-and-play nature of XmAb technologies enables the creation of drug candidates for internal development and the selective licensing and access to one or more XmAb technologies to biopharmaceutical companies to use in developing their own proprietary antibodies with improved properties. Press Releases Nov 21, 2021 Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor Nov 19, 2021 Xencor to Present at Upcoming Investor Conferences View all press releases » Xencor © Copyright 2021 | Privacy Policy